<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two patients with familial <z:hpo ids='HP_0001976'>antithrombin III deficiency</z:hpo> developed <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> of the lower limb </plain></SENT>
<SENT sid="1" pm="."><plain>The diagnosis of <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> was made by the <z:chebi fb="1" ids="30430">indium</z:chebi> labelled platelet technique which also allowed for the daily assessment of <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> size </plain></SENT>
<SENT sid="2" pm="."><plain>Each patient received treatment with <z:chebi fb="8" ids="10033">Warfarin</z:chebi>, subcutaneous <z:chebi fb="5" ids="28304">heparin</z:chebi>, and infusions of antithrombin III concentrates </plain></SENT>
<SENT sid="3" pm="."><plain>The authors conclude that infusions of antithrombin III concentrates may be of value in limiting the extent of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mp ids='MP_0005048'>thrombosis</z:mp> in patients with a severe deficiency of this protein and may help prevent <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The haemorrhagic risk of continuing modest doses of <z:chebi fb="5" ids="28304">heparin</z:chebi> with high dose ATIII therapy appears small </plain></SENT>
<SENT sid="5" pm="."><plain>In addition to its value in the diagnosis of <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> the <z:chebi fb="1" ids="30430">indium</z:chebi> platelet technique may give an early indication of <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> extension and may thus indicate the effectiveness of treatment </plain></SENT>
</text></document>